This study was performed to determine the effects of Hyeolbuchugeotang, which has already been proven to be effective in the treatment of congested and extravasated blood in the field of Oriental medicine, no intravascular coagulation and subcutaneous hematoma.
To do so, an intravascular coagulation was induced in situ by injecting endotoxin in the caudal vein of rats. These rats were then treated with solid extract of Hyeolbuchugeotang (SEH) which was administered orally. Then the numbers of platelets, concentration of fibrinogen and FDP (fibrin fibrinogen degradation products) were measured. Subcutaneous hematoma was produced by the induction of autologous whole blood to produce clotting in situ in rats. SEH was orally administered to the above rats. The lesions were then dissected and observed.
The following results were obtained:
1. The numbers of platelets increased after the administration of SEH and a double dosage of SEH had more significant effects than a single dosage.
2. Related to the concentration of fibrinogen, SEH-treated groups revealed significant increases.
3 As to the effect on the prothrombin time, SEH-treated groups showed significant reductions.
4. Concerning the degree of concentration of FDP, SEH-treated groups revealed significant decreases.
5. The stabilizing effects of SEH on heat-induced hemolysis appeared at 10 and 20mg/ml.
6. 33.3% of the lesions in the control groups enlarged, while none of the lesions in SEH-treated group enlarged.
7. As to the weight of hematoma, SEH-treated groups revealed significant decreases.
8. Histologically, the lesions in SEH-treated groups formed thinner fibroblastic neomembranes than the control groups.
According to the above results, it is concluded that Hyeolbuchugeotang has significant - effects on the numbers of platelets, concentrations of fibrinogen and FDP, pro-thrombin time and heat-induced hemolysis. Hyeolbuchugeotang also inhibited the fibro= blastic neomembrane development and subsequent enlargement of subcutaneous hematoma. Therefore it seems to be applicable to diseases related to thrombosis and hematoma.
|